Examples of using Reactogenicity in English and their translations into Portuguese
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial.
The most important are the issues of the efficacy and reactogenicity of the various vaccines.
Reactogenicity was higher in children receiving whole cell pertussis vaccines concurrently.
There was no evidence of an increased rate of reactogenicity or change in the safety profile of the vaccines in either study.
Reactogenicity was higher in children receiving whole cell pertussis vaccines concomitantly.
Tolerability data of this trial in Belém confirm the previously characterized low reactogenicity of RIX4414 among Finnish infants.
Regardless of age, reactogenicity was higher after the first dose than after the second vaccination.
In the 12-14 months age group who received 2 doses of Nimenrixgiven 2 months apart, the first and second doses were associated with similar local and systemic reactogenicity.
No increase in the reactogenicity was observed after the booster vaccination with respect to the primary vaccination.
Two doses of IMVANEX given at a 7-day interval showed lower immune responses and slightly more local reactogenicity than two doses given at a 28-day interval.
Reactogenicity after a third dose, administered 12 months following the first dose, was higher than after both first and second dose.
Those trials have shown that the safety and reactogenicity profile of the liquid formulation is comparable to the lyophilised formulation.
Reactogenicity after a third dose, administered 12 months after the second dose, was higher than after both first and second dose.
As has been observed for DTPa and DTPa-containing combinations,an increase in local reactogenicity and fever was reported after booster vaccination with Infanrix Penta with respect to the primary course.
Regarding reactogenicity, families reported an increase in adverse effects between the first and third doses in both trials.
The approval was based on results from clinical trials, which investigated the immunogenicity and reactogenicity of Hexavac when administered according to specific primary and booster vaccination schedules.
OBJECTIVE: To compare the reactogenicity of three yellow fever(YF) vaccines from WHO-17D and Brazilian 17DD substrains(different seed-lots) and placebo.
They display a similar genotype to the M. bovis, but have different genotype and phenotype characteristics, with different forms relating to their viability,immunogenicity, reactogenicity and remaining virulence.
The reactogenicity profile of Fendrix in healthy subjects was generally comparable to that seen in pre- haemodialysis and haemodialysis patients.
Clinical trials involving the administration of 2476 doses of Fendrix to 82 pre-haemodialysis and haemodialysis patients andto 713 healthy subjects≥ 15 years of age allowed to document the reactogenicity of the vaccine.
The reactogenicity profile of Fendrix in a total of 82 pre-haemodialysis and haemodialysis patients was generally comparable to that seen in healthy subjects.
Assessment of other vaccines was not feasible in this setting butthe well known reactogenicity profile of those vaccines, make it rather unlikely that one vaccine will be blamed for the adverse events caused by another.
Reactogenicity for common adverse events of the DTwP/Hib vaccine currently used by Brazilian NIP has already been found to be similar to a reference DTwP/Hib vaccine Clemens.
However, it is noteworthy that the RCTs that evaluate the safety and reactogenicity of the vaccine include a limited number of subjects when compared with the general population of individuals eligible for vaccination.
During the pre and post-licensure trials, excellent immunogenicity in the short-term and presence of immunologic memory associated to available conjugate vaccines were demonstrated,besides adequate tolerability and reactogenicity profiles.
The reactogenicity profile and rates of adverse events among subjects aged 56-65 years who received Menveo(N=216), were similar to that observed in Menveo recipients subjects aged 11-55.
The administration of a second half adult oran adult dose did not enhance the reactogenicity, except for rates of general symptoms which were higher after the second dose, particularly for rates of fever in< 6 year olds.
Safety and reactogenicity evaluations were performed for all subjects during the first 3 weeks following vaccination and SAEs have been collected for approximately 3100 vaccinees during six months of follow-up.
Phase I clinical trial, randomized, with two parallel groups, double-blind,which compared immunogenicity and reactogenicity of tetravalent bacterial vaccine with whole cell pertusis DTPw/Hib, with the one with modified pertussis DTPm/Hib.
Reactogenicity was also evaluated in healthy adults aged 18-60 years who received a first 0.5 ml dose of either Arepanrix(H1N1)(N=167) or an AS03-containing vaccine containing HA from H1N1v manufactured using a different process N=167.